^
Association details:
| Biomarker: | EML4-ALK fusion + ALK rearrangement |
|---|---|
| Cancer: | Lung Cancer |
| Drug: | Xalkori (crizotinib) (ALK inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Characterizing kinase intergenic-breakpoint rearrangements in a large-scale lung cancer population and real-world clinical outcomes
Published date:
03/17/2022
Excerpt:
...three ALK IGR patients who harbored no canonical oncogenic aberrations were confirmed with an EML4-ALK chimeric fusion product by RNA sequencing and/or ALK immunohistochemical assays. One patient demonstrated a favorable clinical outcome after 14 months on crizotinib.
DOI:
https://doi.org/10.1016/j.esmoop.2022.100405
